New test could make MS diagnosis faster and easier

NCT ID NCT07183020

ENROLLING_BY_INVITATION Diagnosis Sponsor: Skripuletz, Thomas Prof. Dr. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at whether measuring kappa free light chains (KFLC) in spinal fluid can replace the standard test (oligoclonal bands) for diagnosing multiple sclerosis (MS) and its early stage, clinically isolated syndrome (CIS). Researchers will compare both tests in over 1,100 patients aged 18 to 70. If KFLC works as well, it could simplify diagnosis.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If KFLC testing proves as good or better than current methods, it could simplify and speed up diagnosis for MS and related conditions.
What could go wrong: This is an observational study, not a treatment trial. The results may show KFLC is no better than existing tests, and findings may not change current practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLINICALLY ISOLATED SYNDROME (CIS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

disease multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLINICALLY ISOLATED SYNDROME (CIS) MULTIPLE SCLEROSIS

Contacts and locations

Locations

Medizinische Hochschule Hannover / Hannover Medical School

Hanover, Lower Saxony, 30625, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.